Search results
British drugmaker seeks to acquire D.C. biotech for $466M - Washington Business Journal
The Business Journals· 1 day ago-based Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has received another, even higher, unsolicited...
Cycle Pharma Makes Takeover Bid for Vanda Pharmaceuticals, Sources Say
Bloomberg· 2 days agoCycle Pharmaceuticals Ltd. has made an unsolicited takeover approach for Vanda Pharmaceuticals Inc., according to people familiar with the matter.
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 6 days agoAbbVie is a stock that covers all of the...Dividend King with 52 consecutive years of dividend increases. Since spinning off from Abbott 11 years ago,...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 4 days ago"But we have a large portfolio of existing products, several blockbusters ... growing strongly...May...
GSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
Bloomberg via Yahoo Finance· 5 days ago(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside...
Bill Ackman Wants Your Money. Should You Buy Pershing Square USA?
Barrons.com· 1 day agoThe timing is good for Ackman, who is riding high after a rough period from 2015 to 2017 when he...
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal - Vanda Pharma...
Benzinga· 2 days agoVanda Pharmaceuticals Inc. VNDA received an acquisition offer from Cycle Pharmaceuticals Ltd worth $8 per share, representing a total cash consideration ...
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists
Reuters via AOL· 2 days agoEmployees of drugmaker WuXi AppTec, under U.S. scrutiny for its links to the Chinese military,...
GSK acquires oligonucleotide drug startup Elsie
BioPharma Dive via Yahoo Finance· 2 days agoBritish drugmaker GSK is investing further in nucleic acid drug development, reaching a deal to buy the San Diego-based Elsie Biotechnologies...efforts...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 7 days agoIn that setting, Imfinzi competes with Roche’s immunotherapy Tecentriq. Amgen’s new dual-acting drug...